Hhlr Advisors, Ltd. T Scan Therapeutics, Inc. Transaction History

Hhlr Advisors, Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.65 - $3.58 $1.1 Million - $2.4 Million	-669,513 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.8 - $5.4 $1.72 Million - $3.31 Million	-613,463 Reduced 47.82%	669,513 $1.88 Million
Q3 2021 Nov 15, 2021	BUY	$6.17 - $13.48 $7.92 Million - $17.3 Million	1,282,976 New	1,282,976 $10.7 Million

41.8M

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $55.5M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.